Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory High-Risk neuroblastoma patients.

Next Previous
Trial Profile

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory High-Risk neuroblastoma patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dinutuximab beta (Primary) ; Aldesleukin; Isotretinoin
  • Indications Neuroblastoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Apeiron Biologics

Most Recent Events

  • 28 Jul 2023 According to a Recordati media release, to obtain FDA approval of a Biologics License Application (BLA) for the registration of Qarziba in the United States, preparatory activities are ongoing for a Type C Meeting with the FDA, expected in second half of 2023.
  • 05 Jun 2018 Results assessing a correlation between lymphocyte subsets, functional immune-parameters and survival in patients treated with ch14.18/CHO combined with interleukin-2 , presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
  • 18 Dec 2017 According to an APEIRON Biologics media release, results of this study were a key component of Marketing Authorisation Application for dinutuximab beta to the European Medicines Agency granted in May, 2017. Data will be used for Biologics Licence Application (BLA) to the FDA in the U.S. which is expected during 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top